^
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Thyroid Gland Anaplastic Carcinoma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Thyroid Gland Papillary Carcinoma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive
:
A1
No biomarker
Thyroid Gland Carcinoma
cabozantinib tablet
Sensitive
:
A1
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
selpercatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive
:
A1
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Carcinoma
lenvatinib
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive
:
A2
No biomarker
Thyroid Gland Medullary Carcinoma
dacarbazine
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
CaT
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive
:
A2
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
pembrolizumab
Sensitive
:
A2
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
denosumab
Sensitive
:
A2
No biomarker
Thyroid Gland Follicular Carcinoma
denosumab
Sensitive
:
A2
TMB-H
Thyroid Gland Follicular Carcinoma
pembrolizumab
Sensitive
:
A2
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
selpercatinib
Sensitive
:
A2